The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Multicenter randomized double-blind controlled phase III study of hhpg-19K as prophylactic therapy in patients with advanced non-small cell lung cancer (NSCLC) receiving myelosuppressive chemotherapy.
Caicun Zhou
Consultant or Advisory Role - Boehringer Ingelheim; Lilly; Roche
Yunchao Huang
No relevant relationships to disclose
Changshan An
No relevant relationships to disclose
Donglin Wang
No relevant relationships to disclose
Jianxing He
No relevant relationships to disclose
Fuxiang Zhou
No relevant relationships to disclose
Gongyan Chen
No relevant relationships to disclose
Yali Li
No relevant relationships to disclose
Changping Wu
No relevant relationships to disclose
Gang Wu
No relevant relationships to disclose
Xia Song
No relevant relationships to disclose
Jianfei Gao
No relevant relationships to disclose
Wei Liu
No relevant relationships to disclose
Baolan Li
No relevant relationships to disclose
Jianhua Shi
No relevant relationships to disclose
Cheng Huang
No relevant relationships to disclose
Ping Yu
No relevant relationships to disclose
Jueping Feng
No relevant relationships to disclose
Yi Liu
No relevant relationships to disclose
Jielai Xia
No relevant relationships to disclose